LifeSprout, a Baltimore, Md.-based regenerative medicine company founded with technology licensed from Johns Hopkins University, closed a $28.5m Series A financing.
The round was led by Redmile Group, with participation from new institutional investors Nexus Management, LP, Emerald Development Managers, LP, and the Abell Foundation.
The company intends to use the funds for clinical development of novel therapeutic products from its Regenerative Matrix platform.
Led by Sashank Reddy, MD, PhD, co-founder, and Adam Gridley, Executive Chairman, LifeSprout has developed a proprietary Regenerative Matrix platform which comprises biomimetic, biocompatible materials engineered to look and feel like natural tissue. The first product from this platform – Lumina™ – is a next-generation aesthetic filler that combines the proven safety of hyaluronic acid with biostimulatory effects. The company is developing additional cell therapy products designed to offer regenerative solutions, including treatments for patients with orphan diseases.
